174 related articles for article (PubMed ID: 11401195)
1. Differentiation of the low-molecular-weight heparins.
Racine E
Pharmacotherapy; 2001 Jun; 21(6 Pt 2):62S-70S; discussion 71S-72S. PubMed ID: 11401195
[TBL] [Abstract][Full Text] [Related]
2. [Is there a difference between low-molecular-weight heparins?].
Eritsland J
Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2802-3. PubMed ID: 16244685
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.
Lopez LM
Pharmacotherapy; 2001 Jun; 21(6 Pt 2):56S-61S; discussion 71S-72S. PubMed ID: 11401194
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
Florian-Kujawski M; Hoppensteadt D; Maddineni J; Ziegler H; Fareed J
Int Angiol; 2004 Dec; 23(4):346-54. PubMed ID: 15767980
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of low molecular weight heparin.
Fletcher JP; Ao PY; Hawthorne WJ
ANZ J Surg; 2004 Sep; 74(9):793-6. PubMed ID: 15379813
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
Morris TA; Jacobson A; Marsh JJ; Lane JR
Thromb Res; 2005; 115(1-2):45-51. PubMed ID: 15567452
[TBL] [Abstract][Full Text] [Related]
7. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Martineau P; Tawil N
Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
[TBL] [Abstract][Full Text] [Related]
9. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
10. The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
Mousa SA
Cardiovasc Drug Rev; 2002; 20(3):199-216. PubMed ID: 12397367
[TBL] [Abstract][Full Text] [Related]
11. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
12. Structural features of low-molecular-weight heparins affecting their affinity to antithrombin.
Bisio A; Vecchietti D; Citterio L; Guerrini M; Raman R; Bertini S; Eisele G; Naggi A; Sasisekharan R; Torri G
Thromb Haemost; 2009 Nov; 102(5):865-73. PubMed ID: 19888521
[TBL] [Abstract][Full Text] [Related]
13. Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments.
Alekseeva A; Casu B; Cassinelli G; Guerrini M; Torri G; Naggi A
Anal Bioanal Chem; 2014 Jan; 406(1):249-65. PubMed ID: 24253408
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of LMWHs.
Samama MM; Gerotziafas GT
Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic equivalency of low-molecular-weight heparins.
McCart GM; Kayser SR
Ann Pharmacother; 2002 Jun; 36(6):1042-57. PubMed ID: 12022908
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
19. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.
Mahé I; Aghassarian M; Drouet L; Bal Dit-Sollier C; Lacut K; Heilmann JJ; Mottier D; Bergmann JF
Thromb Haemost; 2007 Apr; 97(4):581-6. PubMed ID: 17393021
[TBL] [Abstract][Full Text] [Related]
20. Can we differentiate the low-molecular-weight heparins?
Turpie AG
Clin Cardiol; 2000 Jan; 23 Suppl 1(Suppl):I4-7. PubMed ID: 10680037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
